Gene TherapyReported
A Very Young Duchenne Patient Was Dosed With Investigational Microdystrophin Gene Therapy
Solid Biosciences reported a pediatric dosing milestone in the SGT-003 program, including a very young patient, alongside safety caveats and Phase 3 movement.
Why now
The update combines a powerful pediatric dosing milestone with a transition toward Phase 3, making it shareable only if the investigational boundary stays visible.
- Overclaim risk
- high
- Primary source
- Company
- Published
- Jun 27, 2026